Pustular psoriasis

Summary

Pustular psoriasis (MONDO:0022205) is a disease and 10 clinical trials. Top therapeutic interventions include anakinra, guselkumab, and infliximab. A subtype of psoriasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pustular psoriasis
Mondo ID	MONDO:0022205
ICD-11	64081271
SNOMED CT	200973000
UMLS	C0152081
MedGen	508876
Is cancer (heuristic)	no

Also known as: pustular psoriasis

Disease family

This is a subtype of psoriasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › psoriasis › pustular psoriasis

Related subtypes (2): psoriasis 2, guttate psoriasis

Subtypes (2): palmoplantar pustulosis, generalized pustular psoriasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01680159	PHASE3	COMPLETED	A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
NCT02343744	PHASE3	COMPLETED	An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT01794117	PHASE2	COMPLETED	Anakinra for Inflammatory Pustular Skin Diseases
NCT04359394	Not specified	RECRUITING	International Rare And Severe Psoriasis Expert Network
NCT01952275	Not specified	UNKNOWN	Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
NCT03885089	Not specified	COMPLETED	Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Psoriasis)
NCT05144165	Not specified	UNKNOWN	Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines
NCT05215561	Not specified	COMPLETED	Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
NCT07428915	Not specified	COMPLETED	Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
NCT07428941	Not specified	COMPLETED	Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ANAKINRA	4	1
GUSELKUMAB	4	1
INFLIXIMAB	4	1
CHEMBL5220618	0	1